{
    "2019-03-14": [
        [
            {
                "time": "2018-01-02",
                "original_text": "Roche Receives EC Approval for Label Expansion of Hemlibra",
                "features": {
                    "keywords": [
                        "Roche",
                        "EC Approval",
                        "Label Expansion",
                        "Hemlibra"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "3 Dividend Aristocrats to Buy and Hold Forever",
                "features": {
                    "keywords": [
                        "Dividend Aristocrats",
                        "Buy",
                        "Hold",
                        "Forever"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividends",
                        "investing"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "The Timely Ten- Blue Chip Buys with Value and Yield",
                "features": {
                    "keywords": [
                        "Timely Ten",
                        "Blue Chip",
                        "Value",
                        "Yield"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "blue chip",
                        "value investing"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades",
                "features": {
                    "keywords": [
                        "Blue Chip",
                        "Drug Stocks",
                        "Reckoning",
                        "Downgrades"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}